Oral Drug Absorption, Evaluation, and Prediction

Developing Solid Oral Dosage Forms

Volumn , Issue , 2009, Pages 289-308

  Yang, Yongsheng ^a   Yu, Lawrence X ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859597344     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53242-8.00012-6     Document Type: Chapter

References (95)

1. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research 1995, 12:413-420.
2. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M-L., Lee V.H., Hussain A.S. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharmaceutical Research 2002, 19:921-925.
3. Polli J.E., Yu L.X., Cook J.A., Amidon G.L., Borchardt R.T., Burnside B.A., Burton P.S., Chen M-L., Conner D.P., Faustino P.J., Hawi A., Hussain A.S., et al. Summary workshop report: Biopharmaceutics classification system-Implementation challenges and extension opportunities. Journal of Pharmaceutical Sciences 2004, 93:1375-1381.
4. Cheng C-L., Yu L.X., Lee H-L., Yang C-Y., Lue C-S., Chou C-H. Biowaiver extension potential to BCS class III high solubility-low permeability drugs: Bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences 2004, 22:297-304.
5. Wu C.Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 2005, 22:11-23.
6. Fleisher D., Li C., Zhou Y., Pao L.H., Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clinical Pharmacokinetics 1999, 36:233-254.
7. Lennernäs H., Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. The Journal of Pharmacy and Pharmacology 2004, 57:273-285.
8. Guidance for Industry. (1995). Immediate Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes. November, CDER/FDA.
9. Guidance for industry. (1997). Dissolution Testing of Immediate Release Solid Oral Dosage Forms. August, CDER/FDA.
10. Guidance for industry. (2000). Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August, CDER/FDA.
11. Buffer solutions. (2006). USP-NF Online. United States Pharmacopeia 29/National Formulary 24. Accessed December 12, 2006.
12. Dissolution. (2006). USP-NF Online. United States Pharmacopeia 29/National Formulary 24. Accessed December 12, 2006.
13. Lennernäs H., Ahrenstedt O., Hällgren R., Knutson L., Ryde M., Paalzow L.K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharmaceutical Research 1992, 9:1243-1251.
14. Oh D.M., Curl R.L., Amido G.L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: A mathematical model. Pharmaceutical Research 1993, 10:264-270.
15. Rekhi G.S., Eddington N.D., Fossler M.J., Schwarts P., Lesko L.J., Augsburger L.L. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. Pharmaceutical Development and Technology 1997, 2:11-24.
16. Yu L.X. An integrated model for determining causes of poor oral drug absorption. Pharmaceutical Research 1999, 16:1883-1887.
17. Delie F., Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption of the Caco-2 model. Critical Reviews in Therapeutic Drug Carrier Systems 1997, 14:221-286.
18. Hidalgo I., Raub T., Borchardt R. Characterization of human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96:739-749.
19. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications 1991, 175:880-885.
20. Rubas W., Jezyk N., Grass G.M. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharmaceutical Research 1993, 10:113-118.
21. Borchardt R. The application of cell culture systems in drug discovery and development. Journal of Drug Targeting 1995, 3:179-182.
22. Autursson P., Palm K., Luthman K. Caco-2 mono-layers in experimental and theoretical predictions of drug transport. Advanced Drug Delivery Reviews 1996, 22:67-84.
23. Volpe, D.A., Ciavarella, A.B., Asafu-Adjaye, E.B., Ellison, C.D., Faustino, P.J. & Yu, L.X. (2001). Method suitability of a Caco-2 cell model for drug permeability classification. AAPS PharmSci. 2001 AAPS Annual Meeting Supplement.
24. Anderle P., Niederer E., Rubas W., Hilgendorf C., Spahn-Langguth H., Wunderli-Allenspach H., Merkle H.P., Langguth P. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. Journal of Pharmaceutical Sciences 1998, 87:757-762.
25. Kim D.C., Burton P.S., Borchardt R.T. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharmaceutical Research 1993, 10:1710-1714.
26. Conradi R.A., Wilkinson K.F., Rush B.D., Hilgers A.R., Ruwart M.J., Burton P.S. In vitro/in vivo models for peptide oral absorption: Comparison of Caco-2 cell permeability with rat intestinal absorption of rennin inhibitory peptides. Pharmaceutical Research 1993, 10:1790-1792.
27. Wils P., Warnery A., Phung-Ba V., Scherman D. Differentiated intestinal epithelial cell lines as in vitro models for predicting the intestinal absorption of drugs. Cell Biology and Toxicology 1994, 10:393-397.
28. Walter E., Janich S., Roessler B.J., Hilfinger J.M., Amidon G.L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. Journal of Pharmaceutical Sciences 1996, 85:1070-1076.
29. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo small intestine absorption in man-fact or myth. Pharmaceutical Research 1997, 14:763-766.
30. Lennernäs H., Ahrenstedt Ö., Hallgren R., Knutson L., Ryde M., Paalzow L.K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharmaceutical Research 1992, 9:1243-1251.
31. Lennernäs H., Palm K., Fagerholm U., Artursson P. Correlation between paracellular and transcellular drug permeability in the human jejunum and Caco-2 monolayers. International Journal of Pharmaceutics 1996, 127:103-107.
32. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin-Darby canine kidney cells): a tool for membrane permeability screening. Journal of Pharmaceutical Sciences 1999, 88:28-33.
33. Cho M., Thompson D., Cramer C., Vidmar T., Scieszka J. The Madin-Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharmaceutical Research 1989, 6:71-79.
34. Putnam W.S., Ramanathan S., Pan L., Takahashi L.H., Benet L.Z. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. Journal of Pharmaceutical Sciences 2002, 91:2622-2635.
35. Gres M., Julian B., Bourrie M., Roques C., Berger M., Boulenc X., Berger Y., Fabre G. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial cell line: comparison with the parental Caco-2 cell line. Pharmaceutical Research 1998, 15:726-733.
36. Li H., Chung S.J., Shim C.K. Characterization of the transport of uracil across Caco-2 and LLC-PK1 cell monolayers. Pharmaceutical Research 2002, 19:1495-1501.
37. Adachi Y., Suzuki H., Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharmaceutical Research 2003, 20:1163-1169.
38. Tavelin S., Taipalensuu J., Hallbook F., Vellonen K.S., Moore V., Artursson P. An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: Characterization of transport routes. Pharmaceutical Research 2003, 20:373-381.
39. Tavelin S., Taipalensuu J., Soderberg L., Moore V., Chong S., Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharmaceutical Research 2003, 20:397-405.
40. Chong S., Dando S., Soucek K., Morrison R. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharmaceutical Research 1996, 13:120-123.
41. Artursson P., Borchardt R.T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharmaceutical Research 1997, 14:1655-1658.
42. Wilson T.H., Wiseman G. The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. The Journal of Physiology 1954, 123:116-125.
43. Rowland R.N., Woodley J.F. The uptake of distearyphosphatidylcholine/cholesterol liposomes by rat intestinal sac in vitro. Biochimica et Biophysica Acta 1981, 673:217-223.
44. Rowland R.N., Woodley J.F. The uptake of free and liposome entrapped horse radish peroxidase by rat intestinal sacs in vitro. FEBS letters 1981, 123:41-44.
45. Carreno-Gomez B., Woodley J.F., Florence A.T. Study on the uptake of nanoparticles in everted gut sacs. International Journal of Pharmaceutics 1999, 183:7-11.
46. Pato J., Mora M., Naisbett B., Woodley J.F., Duncan R. Uptake and transport of poly(N-vinylpyrrolidone-co-maleic acid) by the adult rat small intestine cultured in vitro: effect of chemical structure. International Journal of Pharmaceutics 1994, 110:227-237.
47. Barthe L., Bessouet M., Woodley J.F., Houin G. An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine. European Journal of Drug Metabolism and Pharmacokinetics 1998, 23:313-323.
48. Ussing H.H., Zerahn K. Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Physiologica Scandinavica 1951, 23:110-127.
49. Grass G.M., Sweetana S.A. In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharmaceutical Research 1988, 5:372-376.
50. Smith P., Mirabelli C., Fondacaro J., Ryan F., Dent J. Intestinal 5-fluorouracil absorption: Use of Ussing chambers to assess transport and metabolism. Pharmaceutical Research 1988, 5:598-603.
51. Annaert P., Tukker J.J., van Gelder J., Naesens L., de Clercq E., van Den Mooter G., Kinget R., Augustijins P. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. Journal of Pharmaceutical Sciences 2000, 89:1054-1062.
52. Ungell A.L., Nylander S., Bergstrand S., Sjöberg Å., Lennernäs H. Membrane transport of drugs in different regions of the intestinal tract of the rat. Journal of Pharmaceutical Sciences 1998, 87:360-366.
53. Biosset M., Botham R.P., Haegele K.D., Lenfant B., Pachot P.I. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: Importance of drug ionization in the in vitro prediction of in vivo absorption. Eur.J.Pharm. 2000, 10:215-224.
54. Naruhashi K., Tamai I., Inoue N., Muraoka H., Sai Y., Suzuki N., Tsuji A. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. The Journal of Pharmacy and Pharmacology 2001, 53:699-709.
55. Gotoh Y., Suzuki H., Kinoshita S., Hirohashi T., Kato Y., Sugiyama Y. Involvement of an organic anion transporter (Canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. The Journal of Pharmacology and Experimental Therapeutics 2000, 292:433-439.
56. Hu M., Roland K., Ge L., Chen J., Li Y., Tyle P., Roy S. Determination of absorption characteristics of AG337, a novel thymiddylate synthase inhibitor, using a perfused rat intestinal model. Journal of Pharmaceutical Sciences 1998, 87:886-890.
57. Annaert P., Kinget R., Naesens L., de Clercq E., Augustijins P. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharmaceutical Research 1997, 14:492-496.
58. Okudaira N., Tatebayashi T., Speirs G.C., Komiya I., Sugiyama Y. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: Active efflux transport as a cause of poor bioavailability of the active drug. The Journal of Pharmacology and Experimental Therapeutics 2000, 294:580-587.
59. Stewart B.H., Chan O.H., Lu R.H., Reyner E.L., Schmid H.L., Hamilton H.W., Steinbaugh B.A., Taylor M.D. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans. Pharmaceutical Research 1995, 12:693-699.
60. Fagerholm U., Johansson M., Lennernäs H. Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical Research 1996, 13:1336-1342.
61. Lennernäs H. Human intestinal permeability. Journal of Pharmaceutical Sciences 1998, 87:403-410.
62. Uhing M.R., Kimura R.E. The effect of surgical bowl manipulation and anesthesia on intestinal glucose absorption in rats. The Journal of Clinical Investigation 1995, 95:2790-2798.
63. Yuasa H., Matsuda K., Watanabe J. Influence of anesthetic regimens on intestinal absorption in rats. Pharmaceutical Research 1993, 10:884-888.
64. Chiou W. Determination of drug permeability in a flat or distended stirred intestine. International Journal of Clinical Pharmacology and Therapeutics 1994, 32:474-482.
65. Knutson L., Odlind B., Hällgren R. A new technique for segmental jejunal perfusion in man. The American Journal of Gastroenterology 1989, 84:1278-1284.
66. Lennernäs H., Fagerholm U., Raab Y., Gerdin B., Hällgren R. Regional rectal perfusion, a new in vivo approach to study rectal drug absorption in man. Pharmaceutical Research 1995, 12:426-432.
67. Lennernäs H., Lee I.D., Fagerholm U., Amidon G.L. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: In-vivo permeability estimation. The Journal of Pharmacy and Pharmacology 1997, 49:682-686.
68. Gramatté T., el Desoky E., Klotz U. Site-dependent small intestinal absorption of ranitidine. European Journal of Pharmacology 1994, 46:253-259.
69. Gramatté T., Oertel R., Terhaag B., Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-block tailinolol in humans. Clinical Pharmacology and Therapeutics 1996, 59:541-549.
70. Ewe K., Summerskill W.H. Transfer of ammonia in the human jejunum. The Journal of Laboratory and Clinical Medicine 1965, 65:839-847.
71. Lipinski T., Lombardo F., Dominy B., Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997, 23:3-25.
72. Yu L.X., Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. International Journal of Pharmaceutics 1999, 186:119-125.
73. Yoshida F., Topliss J.G. QSAR model for drug human oral bioavailability. Journal of Medicinal Chemistry 2000, 43:2575-2585.
74. Andrews W.C., Bennett L., Yu L.X. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharmaceutical Research 2000, 17:639-644.
75. Sugawara M., Takekuma Y., Yamada H., Kobayashi M., Iseki K., Miyazaki K. A general approach for the prediction of the intestinal absorption of drugs: regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. Journal of Pharmaceutical Sciences 1998, 87:960-966.
76. Winiwarter S., Bonham N.M., Ax F., Hallberg A., Lennernäs H., Karlen A. A general approach for the prediction of the intestinal absorption of drugs: Regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. Journal of Medicinal Chemistry 1998, 41:4939-4949.
77. Bermejo M., Merino V., Garrigues T.M., Pla-Delfina J.M., Mulet A., Vizet P., Trouiller G., Mercier C. Validation of a biophysical drug absorption model by the PATQSAR system. Journal of Pharmaceutical Sciences 1999, 88:398-405.
78. Yu L.X., Crison J.R., Amidon G.L. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. International Journal of Pharmaceutics 1996, 140:111-118.
79. Yu L.X., Amidon G.L. Characterization of small intestinal transit time distribution in humans. International Journal of Pharmaceutics 1998, 171:157-163.
80. Hirono S., Nakagome I., Hirano H., Matsushita Y., Yoshii F., Moriguchi I. Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: Oral bioavailability. Biological & Pharmaceutical Bulletin 1994, 17:306-309.
81. Bains W., Gilbert R., Sviridenko L., Gascon J.M., Scoffin R., Birchall K., Harvey I., Caldwell J. Evolutionary computational methods to predict oral bioavailability QSPRs. Current Opinion in Drug Discovery & Development 2002, 5:44-51.
82. van de Waterbeemd H. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Current Opinion in Drug Discovery & Development 2002, 5:33-43.
83. Palm K., Stenberg P., Luthman K., Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharmaceutical Research 1997, 14:568-571.
84. Krarup L.H., Christensen I.T., Hovgaard L., Frokjaer S. Predicting drug absorption from molecular surface properties based on molecular dynamics simulations. Pharmaceutical Research 1998, 15:972-978.
85. Stenberg P., Luthman K., Artursson P. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties. Pharmaceutical Research 1999, 16:205-212.
86. Goodwin J.T., Mao B., Vidmar T.J., Conradi R.A., Burton P.S. Strategies toward predicting peptide cellular permeability from computed molecular descriptors. Journal of Peptide Research 1999, 53:355-369.
87. Wessel M.D., Jurs P.C., Tolan J.W., Muskal S.M. Prediction of human intestinal absorption of drug compounds from molecular structure. Journal of Chemical Information and Computer Sciences 1998, 38:726-735.
88. Wang J., Krudy G., Xie X.Q., Wu C., Holland G. Genetic algorithm-optimized QSRP models for bioavailability, protein binding, and urinary excretion. Journal of Chemical Information and Modeling 2006, 46:2674-2683.
89. Kitchen D.B., Subramanian G. Computational approaches for modeling human intestinal absorption and permeability. Journal of Molecular Modeling 2006, 12:577-589.
90. Kariv I., Cao H., Marvil P.D., Bobkova E.V., Bukhtiyarov Y.E., Yan Y.P., Patel U., Coudurier L., Chung T.D., Oldenburg K.R. Identification of inhibitors of bacterial transcription/translation machinery utilizing a miniaturized 1536-well format screen. Journal of Biomolecular Screening 2001, 6:233-243.
91. Lahoz A., Gombau L., Donato M.T., Castell J.V., Gomez-Lechon M.J. In vitro ADME medium/high-throughput screening in drug preclinical development. Mini Reviews in Medicinal Chemistry 2006, 6:1053-1062.
92. Van de Waterbeemd H. From in vivo to in vitro/in silico ADME: Progress and challenges. Expert Opinion on Drug Metabolism & Toxicology 2005, 1:1-4.
93. Alsenz J., Haenel E. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharmaceutical Research 2003, 20:1961-1969.
94. Balimane P.V., Patel K., Marino A., Chong S. Utility of 96-well Caco-2 system for increased throughput of P-gp screening in drug discovery. European Journal of Pharmaceutics and Biopharmaceutics 2005, 58:99-105.
95. Fung E.N., Chu I., Li C., Liu T., Soares A., Morrison R., Nomeir A.A. Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/tandem mass spectrometry system. Rapid Communications in Mass Spectrometry 2003, 17:2147-2152.